Following gynecologic laparoscopic surgery, the bowel movement recovery was not delayed by ramosetron. Moreover, ramosetron showed comparable efficacy as dexamethasone in the regulation of postoperative nausea and vomiting.

This study examined the influence of ramosetron on the recovery of bowel function following gynecological laparoscopic surgery.

In this prospective randomized controlled trial, the recruited people (n=88) were randomly allocated to  get either 10 mg dexamethasone prior to anesthesia initiation (Control group), followed by intravenous administration of patient-controlled analgesia (IV-PCA) or 2 ml normal saline prior to anesthesia initiation and 0.6 mg ramosetron (Study group) given with IV-PCA.

Regarding the time to first flatus and the time to first defecation, no profound differences were noted. 

Also, there were no considerable differences in the demand for additional analgesic agents and the frequency of postoperative nausea and vomiting (PONV). Multiple linear regression for assessment of factors influencing the time to first flatus exhibited no substantial outcomes.

Ramosetron did not hinder the recovery of bowel motility following gynecologic laparoscopic surgery and was as efficacious as dexamethasone in managing PONV. Ramosetron can be utilized with IV-PCA without worrying about the delay in the restoration of bowel function.